The Potent and Selective Sulfidopeptide Leukotriene Antagonist, SK&F 104353, Inhibits Aspirin-induced Asthma
- 1 October 1991
- journal article
- clinical trial
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 144 (4) , 957-958
- https://doi.org/10.1164/ajrccm/144.4.957
Abstract
We have determined the effect of prior inhalation of the LTD4 antagonist SK&F 104353 on the response to aspirin ingestion in six aspirin-sensitive asthmatic subjects (five women and one man 31 to 54 yr of age) in a randomized, double-blind, cross-over, placebo-controlled study. Pretreatment with inhaled SK&F 104353 (average nebulized dose, 893 micrograms) inhibited the response by a mean of 47% (p = 0.02). The inhibition was partial, ranging from 43 to 74% in five subjects. In the remaining subject, there was no effect of the drug on the asthmatic response. We conclude that the mechanism of aspirin-induced asthma is at least partially mediated by the leukotrienes in the majority of susceptible patients and that leukotriene antagonists may be useful in the treatment of aspirin-induced asthma.Keywords
This publication has 4 references indexed in Scilit:
- Release of Leukotrienes, Prostaglandins, and Histamine into Nasal Secretions of Aspirin-sensitive Asthmatics during Reaction to AspirinAmerican Review of Respiratory Disease, 1988
- Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and InflammationScience, 1983
- Structure of slow-reacting substance of anaphylaxis from guinea-pig lungNature, 1980
- Intolerance to AspirinAnnals of Internal Medicine, 1968